Cancer Research Cancer Health Disparities Conference 2009  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartorius, C. A.
Right arrow Articles by Horwitz, K. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sartorius, C. A.
Right arrow Articles by Horwitz, K. B.
[Cancer Research 65, 9779-9788, November 1, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

Progestins Initiate a Luminal to Myoepithelial Switch in Estrogen-Dependent Human Breast Tumors without Altering Growth

Carol A. Sartorius1, Djuana M.E. Harvell1, Tianjie Shen1 and Kathryn B. Horwitz1,2

1 Division of Endocrinology, Department of Medicine and 2 Department of Pathology, University of Colorado Health Sciences Center, Aurora, Colorado

Requests for reprints: Carol A. Sartorius, Division of Endocrinology, Department of Medicine, University of Colorado Health Sciences Center, 12801 East 17th Avenue MS8106, Aurora, CO 80045-7163. Phone: 303-724-3941; Fax: 303-724-3920; E-mail: Carol.Sartorius{at}uchsc.edu.

Although long-term clinical use of progestins is associated with an increased incidence of breast cancers, their role in established cancers is unclear. Estrogens are considered to be the main mitogens in the majority of breast cancers. Whether progesterone affects proliferation and/or differentiation is under debate. To assess the role of progesterone in established breast cancers, we used T47D human breast cancer cells that are estrogen receptor (ER) positive and either progesterone receptor (PR) negative or positive for PRA, PRB, or both. These cells were grown as strictly estrogen-dependent solid tumors in ovariectomized female nude mice. Progesterone or medroxyprogesterone acetate (MPA) alone did not support tumor growth, nor did progesterone or MPA given simultaneously with estrogen significantly alter estrogen-dependent tumor growth. However, treatment of mice bearing ER+PR+ but not ER+PR– tumors with either progesterone or MPA increased expression of the myoepithelial cytokeratins (CK) 5 and 6 in a subpopulation of tumor cells. These CK5+/CK6+ cells had decreased expression of luminal epithelial CK8, CK18, and CK19. We conclude that progestins exert differentiative effects on tumors characterized by transition of a cell subpopulation from luminal to myoepithelial. This may not be beneficial, however, because such a phenotype is associated with poor prognosis.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
K. B. Horwitz
Commentary: The Year in Basic Science: Update of Estrogen Plus Progestin Therapy for Menopausal Hormone Replacement Implicating Stem Cells in the Increased Breast Cancer Risk
Mol. Endocrinol., December 1, 2008; 22(12): 2743 - 2750.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. B. Horwitz and C. A. Sartorius
Progestins in Hormone Replacement Therapies Reactivate Cancer Stem Cells in Women with Preexisting Breast Cancers: A Hypothesis
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3295 - 3298.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. B. Horwitz, W. W. Dye, J. C. Harrell, P. Kabos, and C. A. Sartorius
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts
PNAS, April 15, 2008; 105(15): 5774 - 5779.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Liang, C. Besch-Williford, R. A. Brekken, and S. M. Hyder
Progestin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics
Cancer Res., October 15, 2007; 67(20): 9929 - 9936.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Kariagina, M. D. Aupperlee, and S. Z. Haslam
Progesterone Receptor Isoforms and Proliferation in the Rat Mammary Gland during Development
Endocrinology, June 1, 2007; 148(6): 2723 - 2736.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. M. Jacobsen, J. C. Harrell, P. Jedlicka, V. F. Borges, M. Varella-Garcia, and K. B. Horwitz
Spontaneous Fusion with, and Transformation of Mouse Stroma by, Malignant Human Breast Cancer Epithelium
Cancer Res., August 15, 2006; 66(16): 8274 - 8279.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. M. E. Harvell, J. K. Richer, D. C. Allred, C. A. Sartorius, and K. B. Horwitz
Estradiol Regulates Different Genes in Human Breast Tumor Xenografts Compared with the Identical Cells in Culture
Endocrinology, February 1, 2006; 147(2): 700 - 713.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.